Research programme: CNS therapies - Xenon
Alternative Names: CNS 1; CNS therapies research programme - Xenon; Neurological therapies research programme - Xenon; Research programme: neurological therapies - XenonLatest Information Update: 02 Oct 2021
At a glance
- Originator Xenon Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 20 Sep 2005 This programme is still in active development - BIO 2005: Annual International Convention (BIO 2005)
- 29 Jun 2004 Xenon Genetics is now called Xenon Pharmaceuticals
- 14 Nov 2002 Early research in CNS disorders in Canada (unspecified route)